Celcuity (NASDAQ:CELC) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

Celcuity (NASDAQ:CELC) had its price objective boosted by Needham & Company LLC from $95.00 to $122.00 in a report released on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC’s price target indicates a potential upside of 7.54% from the stock’s current price.

Several other equities research analysts have also recently issued reports on CELC. Weiss Ratings restated a “sell (d-)” rating on shares of Celcuity in a report on Wednesday, January 21st. Craig Hallum increased their price objective on shares of Celcuity from $96.00 to $108.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Wells Fargo & Company started coverage on Celcuity in a research report on Friday, December 12th. They set an “overweight” rating and a $126.00 price objective for the company. HC Wainwright restated a “neutral” rating and issued a $94.00 target price (up from $77.00) on shares of Celcuity in a report on Monday, November 17th. Finally, Jefferies Financial Group raised their target price on shares of Celcuity from $108.00 to $134.00 and gave the stock a “buy” rating in a report on Tuesday, December 2nd. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Celcuity presently has an average rating of “Moderate Buy” and an average price target of $108.63.

Celcuity Stock Performance

Shares of CELC opened at $113.45 on Tuesday. The company has a debt-to-equity ratio of 2.74, a current ratio of 12.26 and a quick ratio of 12.26. Celcuity has a one year low of $7.57 and a one year high of $120.32. The firm has a market capitalization of $5.25 billion, a PE ratio of -30.91 and a beta of 0.38. The company has a 50-day simple moving average of $107.64 and a two-hundred day simple moving average of $85.54.

Insider Buying and Selling at Celcuity

In other Celcuity news, Director David Dalvey sold 20,000 shares of the firm’s stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $120.03, for a total value of $2,400,600.00. Following the completion of the sale, the director directly owned 90,000 shares of the company’s stock, valued at $10,802,700. This trade represents a 18.18% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 15.78% of the stock is currently owned by corporate insiders.

Institutional Trading of Celcuity

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Avoro Capital Advisors LLC acquired a new stake in shares of Celcuity in the fourth quarter valued at approximately $310,302,000. NEA Management Company LLC lifted its holdings in Celcuity by 64.9% in the fourth quarter. NEA Management Company LLC now owns 3,535,561 shares of the company’s stock valued at $352,637,000 after acquiring an additional 1,391,300 shares during the period. State Street Corp lifted its position in shares of Celcuity by 126.6% during the 4th quarter. State Street Corp now owns 1,637,687 shares of the company’s stock valued at $163,343,000 after acquiring an additional 914,887 shares during the period. Apis Capital Advisors LLC purchased a new stake in Celcuity during the third quarter worth $38,334,000. Finally, UBS Group AG grew its stake in Celcuity by 910.1% in the 3rd quarter. UBS Group AG now owns 854,483 shares of the company’s stock valued at $42,211,000 after acquiring an additional 769,891 shares during the last quarter. Institutional investors and hedge funds own 63.33% of the company’s stock.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.